CWS
AGRX

Confluence Wealth Services’s Agile Therapeutics AGRX Stock Holding History

Confluence Wealth Services’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-225
Closed -$2.52K – 266
2023
Q1 		$2.52K Buy
+225
New +$2.89K ﹤0.01% 259

Other funds holding AGRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Confluence Wealth Services's AGRX Position: Q2 2023 in Review

Confluence Wealth Services sold out of Agile Therapeutics (AGRX) in Q2 2023, closing a stake of 225 shares — an estimated $2.52K sold.

Confluence Wealth Services first reported a position in AGRX in Q1 2023 and held it in 1 quarter. The position peaked at $2.52K in Q1 2023. 16 funds tracked by Wall St. Rank hold AGRX as of Q2 2023.

  • Confluence Wealth Services reported no remaining Agile Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Confluence Wealth Services sold 225 Agile Therapeutics shares in Q2 2023, an estimated $2.52K.
  • Confluence Wealth Services first reported a position in Agile Therapeutics in Q1 2023 and held it in 1 quarter.
  • Confluence Wealth Services's Agile Therapeutics position peaked at $2.52K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2023.

Based on Confluence Wealth Services's 13F filing for Q2 2023, filed 1 Aug 2023.